Scott R. Pancoast

Scott Pancoast has served on the board of DermTech [Nasdaq:DMTK] since 2012, helping the CEO grow the company from a raw start to a billion-dollar market cap. From 2005 through 2014, Pancoast was CEO and board member of Lpath [Nasdaq:LPTN] and was Chairman of the company from 1999 through 2010. While at Lpath, his team evolved it from incubation at SDSU to a public company. The team forged partnerships with Pfizer, J&J, Biogen, and Merck Serono and raised about $90 million in investor capital, about $40 million from partnerships, and over $10 million in non-dilutive grants. From 1994 until 2014, he was EVP of Western States Investment Group, where he invested in and managed a portfolio of venture startups ranging from Prisa Networks (sold to EMC) to Endonetics (sold to Medtronic) to Mpex (sold to Axcan, now Allergan) to Vaxiion (now in clinical trials). He also was the executive chairman for several bricks-and-mortar type companies, including an all-cargo airline and Yellow Cab of San Diego. Prior to that, he worked for Chemed Corporation, serving in a variety of roles leading up to President of the Midwest Division and board member of publicly-traded (and Chemed-controlled) National Sanitary Supply [Nasdaq:NSSX]. He has served on over 15 boards, including four public ones; he served as a board member for the San Diego Venture Group for six years and was Chairman for two of those years. Mr. Pancoast holds a BA in economics summa cum laude from the University of Virginia and an MBA with honors from Harvard Business School.